January 31, 2019

Over the past year, major research advances provided new treatment options for patients with rare, difficult-to-treat cancers. In recognition of these achievements, the American Society of Clinical Oncology (ASCO) names “Progress in Treating Rare Cancers” as the Advance of the Year.

January 17, 2019

Five noteworthy studies exploring new approaches in the treatment and management of liver, esophageal, colorectal, and colon cancers will be presented at the 2019 Gastrointestinal Cancers Symposium, taking place January 17-19, 2019 at the Moscone West Building in San Francisco, California.

January 11, 2019

ASCO congratulates Anand Shah, MD, MPH, on being named Senior Medical Advisor for Innovation at the Centers for Medicare & Medicaid Services (CMS). In his new role, Dr. Shah will lead efforts across CMS to advance medical innovation reporting directly to CMS Administrator Seema Verma.

.

January 9, 2019

Statement from American Society of Clinical Oncology (ASCO) President Monica M. Bertagnolli, MD, FACS, FASCO, on the American Cancer Society Cancer Facts and Figures 2019 Report

January 9, 2019

The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration-approved, targeted anticancer drugs that are used for the treatment of patients who have both advanced cancer and a potentially actionable genomic alteration. Tumor profiling testing by a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified, College of American Pathologists-accredited lab is required for patients to enroll in the study.

January 8, 2019

The American Society of Clinical Oncology (ASCO) today published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology. ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify evidence-based safety measures.

January 3, 2019

Advances in medicine and technology are emerging faster than ever before. To harness this momentum, the American Society of Clinical Oncology (ASCO) is convening Breakthrough: A Global Summit for Oncology Innovators – a new meeting focused on the intersection of medicine, scientific discovery, and innovations in technology. The inaugural meeting will take place October 11-13, 2019 at the Centara Grand Hotel CentralWorld in Bangkok, Thailand.

December 18, 2018
The American Society of Clinical Oncology (ASCO) has elected Lori J. Pierce, MD, FASTRO, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2020. ASCO has also elected three additional members to open seats on the Board of Directors, and three members to its ASCO Nominating Committee.
December 17, 2018

Alexandria, Va. – The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) today published a joint analysis comparing the results of both organizations’ value frameworks in ASCO’s Journal of Clinical Oncology (JCO). The analysis found that the frameworks produce comparable measures of the clinical benefits of new therapies in approximately two-thirds of the more than 100 treatment comparisons that were examined. It also identified a number of factors that may contribute to discordant scores, revealing potential ways for both organizations to refine their frameworks in the future.

November 27, 2018

While ASCO supports efforts to control drug prices, we are keenly aware that optimal cancer care requires patient access to the most medically appropriate drug, at the most opportune time, based on the highest quality evidence.

November 15, 2018

The American Society of Clinical Oncology is expanding its geographic reach and the number of international practices certified in delivering high-quality cancer care based on its rigorous standards.

November 13, 2018

An analysis of nearly 2,800 people with non-small cell lung cancer (NSCLC) who received the immune checkpoint inhibitors nivolumab (Opdivo), pembrolizumab (Keytruda), or atezolizumab (Tecentriq) found that unexpected medical problems, known as adverse events, may be more common than reported in the initial trials that led to the approval of these therapies.

November 13, 2018

ALEXANDRIA, Va. – A study of 112 people with metastatic solid tumors found that the use of an artificial intelligence (AI)-based smartphone app reduced both the severity of patients’ reported pain and hospital admissions. After an eight-week period, patients who used the AI-powered app to monitor and address pain experienced a 20% reduction in the severity of pain and had nearly 70% lower risk of pain-related hospital admissions than patients not using the app. These findings will be presented at the upcoming 2018 Palliative and Supportive Care in Oncology Symposium in San Diego, California.

October 30, 2018

The National Cancer Opinion Survey is a large, nationally representative survey conducted online by The Harris Poll.

October 11, 2018

Three prominent medical societies today issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer, the most common malignancy among American men.

Pages